Access the full text.
Sign up today, get DeepDyve free for 14 days.
U. Gatzemeier, A. Płużańska, A. Szczesna, E. Kaukel, J. Roubec, F. Rosa, J. Milanowski, Hanna Karnicka-Mlodkowski, M. Pešek, P. Serwatowski, R. Ramlau, T. Janásková, J. Vansteenkiste, J. Strausz, G. Manikhas, J. Pawel (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 12
L. Sequist (2007)
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.The oncologist, 12 3
L. Sequist, D. Bell, T. Lynch, D. Haber (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 5
Sae-Won Han, Tae-You Kim, P. Hwang, Soohyun Jeong, Jeong-Whun Kim, I. Choi, D. Oh, J. Kim, Dong-Wan Kim, D. Chung, S. Im, Y. Kim, J. Lee, D. Heo, Y. Bang, N. Kim (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
A. Marchetti, C. Martella, L. Felicioni, Fabio Barassi, S. Salvatore, A. Chella, P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, F. Cuccurullo, R. Sacco, F. Buttitta (2005)
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 4
T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi, Seiichiro Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, T. Shibata, T. Sakiyama, Teruhiko Yoshida, T. Tamura (2005)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 28
Sreenath Sharma, Patrycja Gajowniczek, Inna Way, Diana Lee, Jane Jiang, Y. Yuza, M. Classon, D. Haber, J. Settleman (2006)
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.Cancer cell, 10 5
B. Rubin, A. Duensing (2006)
Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumorsLaboratory Investigation, 86
D. Eberhard, B. Johnson, L. Amler, A. Goddard, Sherry Heldens, R. Herbst, William Ince, P. Jänne, T. Januario, David Johnson, P. Klein, V. Miller, M. Ostland, D. Ramies, Dragan Sebisanovic, Jeremy Stinson, Yu Zhang, S. Seshagiri, K. Hillan (2005)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
E. Kwak, Raffaella Sordella, D. Bell, N. Godin-Heymann, R. Okimoto, Brian Brannigan, Patricia Harris, David Driscoll, P. Fidias, T. Lynch, S. Rabindran, J. Mcginnis, A. Wissner, Sreenath Sharma, K. Isselbacher, J. Settleman, D. Haber (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.Proceedings of the National Academy of Sciences of the United States of America, 102 21
Kyu-Sik Kim, Ju-yeon Jeong, Young-chul Kim, K. Na, Y. Kim, S. Ahn, S. Baek, Chang-Soo Park, C. Park, Y. Kim, S. Lim, K. Park (2005)
Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung CancerClinical Cancer Research, 11
L. Sequist, R. Martins, D. Spigel, S. Grunberg, P. Jänne, D. Mccollum, A. Spira, T. Evans, B. Johnson, T. Lynch (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumorsJournal of Clinical Oncology, 25
T. Kosaka, Y. Yatabe, H. Endoh, Kimihide Yoshida, T. Hida, M. Tsuboi, H. Tada, H. Kuwano, T. Mitsudomi (2006)
Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to GefitinibClinical Cancer Research, 12
R. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B. Johnson, A. Sandler, M. Kris, H. Tran, P. Klein, Xin Li, D. Ramies, David Johnson, V. Miller (2005)
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
H. Cortés-Funes, C. Gómez, R. Rosell, P. Valero, C. García-Girón, Ángela Velasco, A. Izquierdo, P. Diz, C. Camps, D. Castellanos, V. Alberola, F. Cardenal, J. González-Larriba, J. Viéitez, I. Maeztu, J. Sánchez, C. Queralt, C. Mayo, P. Méndez, T. Moran, M. Taron (2005)
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.Annals of oncology : official journal of the European Society for Medical Oncology, 16 7
J. Mendelsohn, J. Baselga (2003)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, S. Cuccato, S. Placido, A. Bianco, G. Tortora (2001)
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 5
F. Shepherd, J. Pereira, T. Ciuleanu, E. Tan, V. Hirsh, S. Thongprasert, D. Campos, Savitree Maoleekoonpiroj, M. Smylie, R. Martins, M. Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour (2005)
Erlotinib in previously treated non-small-cell lung cancer.The New England journal of medicine, 353 2
B. Druker, C. Sawyers, H. Kantarjian, D. Resta, Sofia Reese, J. Ford, R. Capdeville, M. Talpaz (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.The New England journal of medicine, 344 14
M. Tsao, A. Sakurada, J. Cutz, Chang-Qi Zhu, S. Kamel‐Reid, J. Squire, I. Lorimer, Tong Zhang, Ni Liu, M. Daneshmand, P. Marrano, G. Santos, A. Lagarde, F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater, F. Shepherd (2005)
Erlotinib in lung cancer - molecular and clinical predictors of outcome.The New England journal of medicine, 353 2
G. Giaccone, R. Herbst, C. Manegold, G. Scagliotti, R. Rosell, V. Miller, R. Natale, J. Schiller, J. Pawel, A. Płużańska, U. Gatzemeier, J. Grous, J. Ochs, S. Averbuch, M. Wolf, P. Rennie, A. Fandi, David Johnson (2004)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 5
M. Veronese, K. Algazy, L. Bearn, B. Eaby, J. Alavi, T. Evans, J. Stevenson, J. Shults (2005)
Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): The Expanded Access Protocol Experience at the University of PennsylvaniaCancer Investigation, 23
F. Cappuzzo, F. Hirsch, E. Rossi, S. Bartolini, G. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, V. Ludovini, E. Magrini, V. Gregorc, C. Doglioni, A. Sidoni, M. Tonato, W. Franklin, L. Crinò, P. Bunn, M. Varella-Garcia (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Journal of the National Cancer Institute, 97 9
M. Ono, Akira Hirata, T. Kometani, M. Miyagawa, Shu-ichi Ueda, H. Kinoshita, T. Fujii, M. Kuwano (2004)
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.Molecular cancer therapeutics, 3 4
N. Thatcher, A. Chang, P. Parikh, J. Pereira, T. Ciuleanu, J. Pawel, S. Thongprasert, E. Tan, K. Pemberton, V. Archer, K. Carroll (2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 366
F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. Placido, A. Bianco, G. Tortora (2000)
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 5
N. Normanno, A. Luca, C. Bianco, L. Strizzi, M. Mancino, M. Maiello, A. Carotenuto, G. Feo, F. Caponigro, D. Salomon (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer.Gene, 366 1
E. Camp, J. Summy, T. Bauer, Wenbiao Liu, G. Gallick, L. Ellis (2005)
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.Clinical cancer research : an official journal of the American Association for Cancer Research, 11 1
L. Paz-Ares, J. Sánchez, A. García-Velasco, B. Massutí, G. López-Vivanco, Mariano Provencio, A. Montes, Dolores Isla, M. Amador, R. Rosell (2006)
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
Susumu Kobayashi, T. Boggon, Tajhal Dayaram, P. Jänne, O. Kocher, M. Meyerson, B. Johnson, M. Eck, D. Tenen, B. Halmos (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 352 8
V. Rusch, J. Baselga, C. Cordon-Cardo, J. Orazem, M. Zaman, S. Hoda, J. McIntosh, J. Kurie, E. Dmitrovsky (1993)
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.Cancer research, 53 10 Suppl
J. Mendelsohn (2002)
Targeting the epidermal growth factor receptor for cancer therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 18 Suppl
M. Decamp, S. Ashiku, R. Thurer (2005)
The Role of Surgery in N2 Non–Small Cell Lung CancerClinical Cancer Research, 11
H. Greulich, Tzu-Hsiu Chen, W. Feng, P. Jänne, James Alvarez, M. Zappaterra, Sara Bulmer, D. Frank, W. Hahn, W. Sellers, M. Meyerson (2005)
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLoS Medicine, 2
I. Weinstein, A. Joe (2006)
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 3
T. Chou, C. Chiu, Ling-Hui Li, C. Hsiao, C. Tzen, Kuo‐Ting Chang, Yuh-Min Chen, R. Perng, S. Tsai, C. Tsai (2005)
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung CancerClinical Cancer Research, 11
H. Asahina, K. Yamazaki, I. Kinoshita, N. Sukoh, M. Harada, H. Yokouchi, T. Ishida, S. Ogura, T. Kojima, Y. Okamoto, Y. Fujita, H. Dosaka-akita, H. Isobe, M. Nishimura, O. Group (2006)
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutationsBritish Journal of Cancer, 95
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. Dong, J. Baselga (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 12
M. Hidalgo, L. Siu, J. Nemunaitis, J. Rizzo, L. Hammond, C. Takimoto, S. Eckhardt, A. Tolcher, C. Britten, L. Denis, K. Ferrante, D. Hoff, S. Silberman, E. Rowinsky (2001)
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 13
R. Perez-soler, A. Chachoua, L. Hammond, E. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. Clark, P. Santabarbara, P. Bonomi (2004)
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 16
J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D. Kieback, S. Kaye, L. Gianni, A. Harris, T. Björk, S. Averbuch, A. Feyereislova, H. Swaisland, F. Rojo, J. Albanell (2002)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 21
W. Evans (2004)
Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.Cancer treatment reviews, 30 7
A. Inoue, Takuji Suzuki, T. Fukuhara, M. Maemondo, Y. Kimura, N. Morikawa, H. Watanabe, Y. Saijo, T. Nukiwa (2006)
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 21
Y. Yarden, M. Sliwkowski (2001)
Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2
H. Shigematsu, Li Lin, Takao Takahashi, M. Nomura, Makoto Suzuki, I. Wistuba, K. Fong, Hue Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Ziding Feng, J. Roth, J. Herz, J. Minna, A. Gazdar (2006)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.Journal of the National Cancer Institute, 97 5
F. Shepherd, M. Tsao (2006)
Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 7
T. Dutu, Stefan Michiels, Pierre Fouret, Frédérique Penault-Llorca, Pierre Validire, Simone Benhamou, E. Taranchon, L. Morat, D. Grunenwald, T. Chevalier, Laure Sabatier, Jeannette Soria (2005)
Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers.Annals of oncology : official journal of the European Society for Medical Oncology, 16 12
Thomas Holbro, G. Civenni, N. Hynes (2003)
The ErbB receptors and their role in cancer progression.Experimental cell research, 284 1
T. Mitsudomi, T. Kosaka, H. Endoh, Y. Horio, T. Hida, S. Mori, S. Hatooka, M. Shinoda, Takashi Takahashi, Y. Yatabe (2005)
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, Takashi Takahashi, T. Mitsudomi (2004)
Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 64
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
V. Grünwald, M. Hidalgo (2003)
Development of the epidermal growth factor receptor inhibitor OSI-774.Seminars in oncology, 30 3 Suppl 6
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David Johnson (2006)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.The New England journal of medicine, 355 24
T. Carter, L. Wodicka, N. Shah, A. Velasco, M. Fabian, D. Treiber, Zdravko Milanov, Corey Atteridge, W. Biggs, Philip Edeen, Mark Floyd, J. Ford, R. Grotzfeld, S. Herrgård, Darren Insko, Shamal Mehta, H. Patel, W. Pao, C. Sawyers, H. Varmus, P. Zarrinkar, D. Lockhart (2005)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.Proceedings of the National Academy of Sciences of the United States of America, 102 31
J. Schiller, D. Harrington, C. Belani, C. Langer, A. Sandler, J. Krook, Junming Zhu, David Johnson (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.The New England journal of medicine, 346 2
Duykhanh Pham, M. Kris, Gregory Riely, I. Sarkaria, T. McDonough, S. Chuai, E. Venkatraman, V. Miller, M. Ladanyi, W. Pao, R. Wilson, Bhuvanesh Singh, V. Rusch (2006)
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 11
Gregory Riely, W. Pao, Duykhanh Pham, Allan Li, N. Rizvi, E. Venkatraman, M. Zakowski, M. Kris, M. Ladanyi, V. Miller (2006)
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or ErlotinibClinical Cancer Research, 12
M. Tarón, Y. Ichinose, R. Rosell, T. Mok, B. Massutí, L. Zamora, J. Maté, C. Manegold, M. Ono, C. Queralt, T. Jahan, J. Sánchez, M. Sánchez-Ronco, V. Hsue, D. Jablons, J. Sánchez, T. Morán (2005)
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung AdenocarcinomasClinical Cancer Research, 11
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
M. Mohamed, S. Ramalingam, Yan Lin, W. Gooding, C. Belani (2005)
Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 16 5
C. Yun, T. Boggon, Yiqun Li, M. Woo, H. Greulich, M. Meyerson, M. Eck (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.Cancer cell, 11 3
R. Herbst, G. Giaccone, J. Schiller, R. Natale, V. Miller, C. Manegold, G. Scagliotti, R. Rosell, I. Oliff, J. Reeves, M. Wolf, A. Krebs, S. Averbuch, J. Ochs, J. Grous, A. Fandi, David Johnson (2004)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 5
K. Yoneda, K. Hardin, D. Gandara, D. Shelton (2006)
Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.Clinical lung cancer, 8 Suppl 1
W. Pao, V. Miller, K. Politi, Gregory Riely, R. Somwar, M. Zakowski, M. Kris, H. Varmus (2005)
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2
M. Kris, R. Natale, R. Herbst, T. Lynch, D. Prager, C. Belani, J. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K. Albain, D. Cella, M. Wolf, S. Averbuch, J. Ochs, A. Kay (2003)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA, 290 16
F. Hirsch, M. Varella-Garcia, P. Bunn, W. Franklin, R. Dziadziuszko, N. Thatcher, A. Chang, P. Parikh, J. Pereira, T. Ciuleanu, J. Pawel, C. Watkins, Angela Flannery, G. Ellison, E. Donald, Lucy Knight, D. Parums, N. Botwood, B. Holloway (2006)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 31
J. Engelman, K. Zejnullahu, T. Mitsudomi, Youngchul Song, Courtney Hyland, Joon-Oh Park, N. Lindeman, Christopher-Michael Gale, Xiaojun Zhao, J. Christensen, T. Kosaka, A. Holmes, A. Rogers, F. Cappuzzo, T. Mok, Charles Lee, B. Johnson, L. Cantley, P. Jänne (2007)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 316
Xiaotong Zhang, L-Y Li, X. Mu, Q. Cui, X.-Y. Chang, W. Song, S-L Wang, Mengzhao Wang, W. Zhong, Lanjun Zhang (2005)
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 16 8
T. Sone, K. Kasahara, H. Kimura, K. Nishio, M. Mizuguchi, Y. Nakatsumi, K. Shibata, Y. Waseda, M. Fujimura, S. Nakao (2007)
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancerCancer, 109
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proceedings of the National Academy of Sciences of the United States of America, 101 36
D. Jackman, B. Yeap, L. Sequist, N. Lindeman, A. Holmes, V. Joshi, D. Bell, M. Huberman, B. Halmos, M. Rabin, D. Haber, T. Lynch, M. Meyerson, B. Johnson, P. Jänne (2006)
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or ErlotinibClinical Cancer Research, 12
Raffaella Sordella, D. Bell, D. Haber, J. Settleman (2004)
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic PathwaysScience, 305
P. Jänne, S. Gurubhagavatula, B. Yeap, J. Lucca, P. Ostler, A. Skarin, P. Fidias, T. Lynch, B. Johnson (2004)
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.Lung cancer, 44 2
F. Hirsch, G. Scagliotti, C. Langer, M. Varella-Garcia, W. Franklin (2003)
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.Lung cancer, 41 Suppl 1
I. Weinstein (2002)
Addiction to Oncogenes--the Achilles Heal of CancerScience, 297
Sae-Won Han, Tae-You Kim, Y. Jeon, P. Hwang, S. Im, Kyung-Hun Lee, J. Kim, Dong-Wan Kim, D. Heo, N. Kim, D. Chung, Y. Bang (2006)
Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt PhosphorylationClinical Cancer Research, 12
D. Bell, T. Lynch, Sara Haserlat, Patricia Harris, R. Okimoto, Brian Brannigan, D. Sgroi, B. Muir, M. Riemenschneider, R. Iacona, A. Krebs, David Johnson, G. Giaccone, R. Herbst, C. Manegold, M. Fukuoka, M. Kris, J. Baselga, J. Ochs, D. Haber (2005)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 31
Drugs that target the epidermal growth factor receptor (EGFR) have had a major impact on the treatment of non–small cell lung cancer (NSCLC). The use of these drugs has also motivated pivotal advances in the understanding of the molecular biology of NSCLC, including the discovery that mutations in EGFR are associated with dramatic and sustained responses to anti-EGFR treatments. This review summarizes the clinical development of EGFR tyrosine kinase inhibitors, the discovery of molecular predictors of response, and the future directions for research in the field.
Annual Review of Medicine – Annual Reviews
Published: Feb 18, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.